Dye, C., Scheele, S., Dolin, P., Pathania, V. & Raviglione, M.C. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. J. Am. Med. Assoc. 282, 677–686 (1999).
Gandhi, N.R. et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368, 1575–1580 (2006).
Colditz, G.A. et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. J. Am. Med. Assoc. 271, 698–702 (1994).
Corbett, E.L. et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163, 1009–1021 (2003).
Hesseling, A.C. et al. The risk of disseminated bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 25, 14–18 (2007).
Hinchey, J. et al. Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J. Clin. Invest. 117, 2279–2288 (2007).
Orme, I.M. Preclinical testing of new vaccines for tuberculosis: a comprehensive review. Vaccine 24, 2–19 (2006).
Skeiky, Y.A. & Sadoff, J.C. Advances in tuberculosis vaccine strategies. Nat. Rev. Microbiol. 4, 469–476 (2006).
Sander, C.R. et al. Safety and immunogenicity of a new TB vaccine, MVA85A, in M. tuberculosis infected individuals. Am. J. Respir. Crit. Care Med. 179, 724–733 (2009).
Armstrong, J.A. & Hart, P.D. Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes. J. Exp. Med. 134, 713–740 (1971).
Fulton, S.A. et al. Inhibition of major histocompatibility complex II expression and antigen processing in murine alveolar macrophages by Mycobacterium bovis BCG and the 19-kilodalton mycobacterial lipoprotein. Infect. Immun. 72, 2101–2110 (2004).
Pai, R.K. et al. Prolonged toll-like receptor signaling by Mycobacterium tuberculosis and its 19-kilodalton lipoprotein inhibits gamma interferon-induced regulation of selected genes in macrophages. Infect. Immun. 72, 6603–6614 (2004).
Dao, D.N. et al. Mycolic acid modification by the mmaA4 gene of M. tuberculosis modulates IL-12 production. PLoS Pathog. 4, e1000081 (2008).
Baena, A. & Porcelli, S.A. Evasion and subversion of antigen presentation by Mycobacterium tuberculosis. Tissue Antigens 74, 189–204 (2009).
Mahairas, G.G., Sabo, P.J., Hickey, M.J., Singh, D.C. & Stover, C.K. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J. Bacteriol. 178, 1274–1282 (1996).
Behr, M.A. et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284, 1520–1523 (1999).
Lewis, K.N. et al. Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette-Guerin attenuation. J. Infect. Dis. 187, 117–123 (2003).
Pym, A.S. et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat. Med. 9, 533–539 (2003).
Stanley, S.A., Raghavan, S., Hwang, W.W. & Cox, J.S. Acute infection and macrophage subversion by Mycobacterium tuberculosis require a specialized secretion system. Proc. Natl. Acad. Sci. USA 100, 13001–13006 (2003).
Hsu, T. et al. The primary mechanism of attenuation of bacillus Calmette-Guerin is a loss of secreted lytic function required for invasion of lung interstitial tissue. Proc. Natl. Acad. Sci. USA 100, 12420–12425 (2003).
MacGurn, J.A. & Cox, J.S. A genetic screen for Mycobacterium tuberculosis mutants defective for phagosome maturation arrest identifies components of the ESX-1 secretion system. Infect. Immun. 75, 2668–2678 (2007).
de Jonge, M.I. et al. ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity. J. Bacteriol. 189, 6028–6034 (2007).
Xu, J. et al. A unique Mycobacterium ESX-1 protein co-secretes with CFP-10/ESAT-6 and is necessary for inhibiting phagosome maturation. Mol. Microbiol. 66, 787–800 (2007).
Smith, J. et al. Evidence for pore formation in host cell membranes by ESX-1-secreted ESAT-6 and its role in Mycobacterium marinum escape from the vacuole. Infect. Immun. 76, 5478–5487 (2008).
van der Wel, N. et al. M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell 129, 1287–1298 (2007).
Gey Van Pittius, N.C. et al. The ESAT-6 gene cluster of Mycobacterium tuberculosis and other high G+C Gram-positive bacteria. Genome Biol. 2, research0044 (2001).
Stinear, T.P. et al. Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis. Genome Res. 18, 729–741 (2008).
Maciag, A. et al. Global analysis of the Mycobacterium tuberculosis Zur (FurB) regulon. J. Bacteriol. 189, 730–740 (2007).
Rodriguez, G.M., Voskuil, M.I., Gold, B., Schoolnik, G.K. & Smith, I. ideR, an essential gene in Mycobacterium tuberculosis: role of IdeR in iron-dependent gene expression, iron metabolism, and oxidative stress response. Infect. Immun. 70, 3371–3381 (2002).
Talaat, A.M., Lyons, R., Howard, S.T. & Johnston, S.A. The temporal expression profile of Mycobacterium tuberculosis infection in mice. Proc. Natl. Acad. Sci. USA 101, 4602–4607 (2004).
Dubnau, E., Chan, J., Mohan, V.P. & Smith, I. Responses of Mycobacterium tuberculosis to growth in the mouse lung. Infect. Immun. 73, 3754–3757 (2005).
Sassetti, C.M., Boyd, D.H. & Rubin, E.J. Genes required for mycobacterial growth defined by high density mutagenesis. Mol. Microbiol. 48, 77–84 (2003).
Sassetti, C.M. & Rubin, E.J. Genetic requirements for mycobacterial survival during infection. Proc. Natl. Acad. Sci. USA 100, 12989–12994 (2003).
Siegrist, M.S. et al. Mycobacterial ESX-3 is required for mycobactin-mediated iron acquisition. Proc. Natl. Acad. Sci. USA 106, 18792–18797 (2009).
Flynn, J.L. & Chan, J. Immunology of tuberculosis. Annu. Rev. Immunol. 19, 93–129 (2001).
Orme, I.M. & Collins, F.M. Protection against Mycobacterium tuberculosis infection by adoptive immunotherapy. Requirement for T cell-deficient recipients. J. Exp. Med. 158, 74–83 (1983).
Pierre-Audigier, C. et al. Fatal disseminated Mycobacterium smegmatis infection in a child with inherited interferon gamma receptor deficiency. Clin. Infect. Dis. 24, 982–984 (1997).
Kumar, K.J., Chandra, J., Mandal, R.N., Dutta, R. & Jain, N.K. Fatal pulmonary infection caused by Mycobacterium smegmatis in an infant. Indian J. Pediatr. 62, 619–621 (1995).
Abdallah, A.M. et al. The ESX-5 secretion system of Mycobacterium marinum modulates the macrophage response. J. Immunol. 181, 7166–7175 (2008).
Raghavan, S., Manzanillo, P., Chan, K., Dovey, C. & Cox, J.S. Secreted transcription factor controls Mycobacterium tuberculosis virulence. Nature 454, 717–721 (2008).
Yang, C. et al. GLS/IL-12-modified Mycobacterium smegmatis as a novel anti-tuberculosis immunotherapeutic vaccine. Int. J. Tuberc. Lung Dis. 13, 1360–1366 (2009).
Yi, Z. et al. Recombinant M. smegmatis vaccine targeted delivering IL-12/GLS into macrophages can induce specific cellular immunity against M. tuberculosis in BALB/c mice. Vaccine 25, 638–648 (2007).
Yeremeev, V.V. et al. The 19-kD antigen and protective immunity in a murine model of tuberculosis. Clin. Exp. Immunol. 120, 274–279 (2000).
Sun, R. et al. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 27, 4412–4423 (2009).
Kita, Y. et al. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. Vaccine 23, 2132–2135 (2005).
van Dissel, J.T. et al. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine 28, 3571–3581 (2010).
Williams, A. et al. Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs. Infect. Immun. 73, 3814–3816 (2005).
Whelan, K.T. et al. Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A. PLoS ONE 4, e5934 (2009).
Vordermeier, H.M. et al. Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect. Immun. 77, 3364–3373 (2009).
Bendelac, A., Bonneville, M. & Kearney, J.F. Autoreactivity by design: innate B and T lymphocytes. Nat. Rev. Immunol. 1, 177–186 (2001).